Home
Product
Antibody
Biosimilar Antibodies
DLL3 (Rovalpituzumab Biosimilar) Recombinant Monoclonal Antibody

DLL3 (Rovalpituzumab Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA882142MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q9NYJ7

Alternative Names

Delta-like protein 3；Drosophila Delta homolog 3；Delta3, DLL3

Species Reactivity

Human

Immunogen

Recombinant Human DLL3 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is a research-grade biosimilar to Rovalpituzumab, designed to specifically target Delta-like protein 3 (DLL3). DLL3 is an atypical member of the Notch ligand family that functions as an inhibitory regulator of Notch signaling during somitogenesis and neuronal development. Unlike canonical Delta-like ligands, DLL3 is primarily retained intracellularly and does not activate Notch signaling in neighboring cells. This protein exhibits aberrant expression in various neuroendocrine tumors, particularly small cell lung cancer (SCLC), where it is highly expressed on the cell surface of tumor cells in approximately 80% of cases, making it an important oncology target.

Rovalpituzumab is a humanized IgG1 monoclonal antibody that was developed as an antibody-drug conjugate (ADC) platform for targeted cancer therapy. This biosimilar antibody provides researchers with a valuable tool for investigating DLL3 biology, studying neuroendocrine tumor pathogenesis, exploring Notch pathway regulation, and developing novel therapeutic strategies for DLL3-expressing malignancies. It serves as an essential reagent for preclinical oncology research and biomarker studies.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm.

Gene References into Functions

these results reveal that DLL3 is expressed in tumor specimens from most patients with small cell lung cancer PMID:29290251
Results indicated that DLL3 expression was silenced in hepatocellular carcinoma (HCC) cells by DNA methylation and was more readily affected by histone acetylation than histone methylation (H3K9me2 or H3K27me3). PMID:29512761
our results indicated epidermal growth factor-like domain multiple 7 protein participates in growth hormone-secreting pituitary adenoma proliferation and invasion regulation via Notch2/DLL3 signaling pathway. These findings raised the possibility that epidermal growth factor-like domain multiple 7 protein might serve as a useful biomarker to assess growth hormone-secreting pituitary adenoma invasion and prognosis PMID:28705113
The Dll3 was rarely detectable in the para-carcinoma tissues, but positive in 82.1% of non-small cell cancer tissues. PMID:28007595
Both global haplotype and individual haplotype analyses showed that the haplotypes of SNP1/SNP2/SNP3/SNP4/SNP5 did not correlate with the disease (P >0.05). Together, these data suggest that genetic variants of the DLL3 gene are not associated with CS in the Chinese Han population. PMID:27472720
DLL3 was silenced by methylation in human human hepatocellular carcinoma and it negatively regulates the growth of human hepatocellular carcinoma cells. PMID:23337976
We suggest that the three human DLL3 mutations associated with spondylocostal dysplasia are also functionally equivalent to the Dll3(neo) null allele in mice. PMID:11923214
mutations in DLL3 cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis PMID:12746394
no novel or previously described mutations are present in our cohort, indicating that DLL3 mutations may not be a major cause of congenital scoliosis. PMID:15717203
The intracellular region of Notch ligands Dll1 and Dll3 regulates their trafficking and signaling activity PMID:18676613